CephalalgiaPub Date : 2026-11-01Epub Date: 2026-11-10DOI: 10.1177/03331024261506157
Qingkui Zhang, Yang Li, Zizi He, Ya Cao, Xiaoxue Lin, Yang Liu, Ye Ran, Zhao Dong, Ruozhuo Liu, Shengyuan Yu
{"title":"Restlessness in cluster headache: Rethinking a classic feature through behaviorally-anchored assessment.","authors":"Qingkui Zhang, Yang Li, Zizi He, Ya Cao, Xiaoxue Lin, Yang Liu, Ye Ran, Zhao Dong, Ruozhuo Liu, Shengyuan Yu","doi":"10.1177/03331024261506157","DOIUrl":"https://doi.org/10.1177/03331024261506157","url":null,"abstract":"<p><p>AimRestlessness/agitation is a formal diagnostic feature of cluster headache (CH), but whether it is identified may depend on which attack-related behaviors are specifically asked about. We aimed to compare the proportions of participants meeting different behavior-based definitions of restlessness/agitation. We also examined whether participants reporting rolling/rocking on bed or floor without an urge to move, pacing/walking, or sitting restlessness had longer delay to first CH awareness.MethodsWe conducted a cross-sectional online survey with an embedded telephone validation substudy within the Chinese Online Registry for Cluster Headache, a patient-community registry in China. Adults with self-reported definite or suspected cluster headache were recruited from two long-standing WeChat patient-support communities in late 2025. After prespecified screening, quality-control procedures, and International Classification of Headache Disorders, 3rd edition (ICHD-3)-based case ascertainment, the final analytic cohort comprised 366 participants. Recognition delay was defined as the interval from first CH symptom onset to first CH awareness. Readily recognized restlessness/agitation comprised an urge to move, pacing/walking, or sitting restlessness; hidden supine-dominant restlessness/agitation comprised rolling/rocking on bed or floor in the absence of an urge to move, pacing/walking, or sitting restlessness. Together, these categories formed the primary behaviorally-anchored restlessness/agitation definition. Extreme self-directed attack-related behaviors were additionally included in a broader exploratory category. Among participants meeting the primary definition, multivariable median regression estimated the adjusted median difference in recognition delay between hidden supine-dominant and readily recognized restlessness/agitation.ResultsThe proportion meeting the readily recognized definition was 202/366 (55.2%), compared with 279/366 (76.2%) under the primary behaviorally-anchored definition; the broader exploratory category included 305/366 participants (83.3%). Among participants meeting the primary behaviorally-anchored definition, hidden supine-dominant restlessness/agitation (<i>n</i> = 77) was associated with longer recognition delay than readily recognized restlessness/agitation (<i>n</i> = 202) before adjustment (median 9.0 vs 7.0 years; P = 0.006) and after adjustment (+3.40 years, 95% CI 1.86 to 4.94; P < 0.001). Among 56 interviewed participants eligible under the final cohort criteria, the positive predictive value for definite CH was 98.2% (55/56; 95% CI, 90.4-100.0).ConclusionIn this online patient-community registry, asking specifically about rolling/rocking on bed or floor identified additional participants who did not report readily recognized components of restlessness/agitation. This response pattern was associated with longer recognition delay. For patients who lie down during an attack, clinicians should ask: \"When you","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 11","pages":"3331024261506157"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2026-11-01Epub Date: 2026-11-03DOI: 10.1177/03331024261501141
Derya Uludüz, Vanda Faria, Ishaq Abu-Arafeh, Serena Laura Orr, Toshiyuki Hikita, Hamit Genç, Aynur Özge
{"title":"Authors' reply to Steiner et al.: \"Migraine and headache in children and adolescents: a 2026 evidence-based factsheet\".","authors":"Derya Uludüz, Vanda Faria, Ishaq Abu-Arafeh, Serena Laura Orr, Toshiyuki Hikita, Hamit Genç, Aynur Özge","doi":"10.1177/03331024261501141","DOIUrl":"https://doi.org/10.1177/03331024261501141","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 11","pages":"3331024261501141"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2026-11-01Epub Date: 2026-11-03DOI: 10.1177/03331024261502429
Marta Waliszewska-Prosół, Samiye Ulutas, Teresa Mateu, Sheharyar Ahmad, Prisca-Rolande Bassolé, Merve Ceren Akgor, Kinga Gecse, Marie Therese Kleinsorge, Nijanth Manohararaj, Selam Kifelew Melkamu, Ignacio Del Pino de Laguno, Sena Uzun, Edoardo Caronna, Patricia Pozo-Rosich
{"title":"Migraine beyond attacks: Insights on the interictal phase.","authors":"Marta Waliszewska-Prosół, Samiye Ulutas, Teresa Mateu, Sheharyar Ahmad, Prisca-Rolande Bassolé, Merve Ceren Akgor, Kinga Gecse, Marie Therese Kleinsorge, Nijanth Manohararaj, Selam Kifelew Melkamu, Ignacio Del Pino de Laguno, Sena Uzun, Edoardo Caronna, Patricia Pozo-Rosich","doi":"10.1177/03331024261502429","DOIUrl":"https://doi.org/10.1177/03331024261502429","url":null,"abstract":"<p><p>BackgroundTraditionally, migraine has been characterized by its paroxysmal attacks, with the interictal phase considered to be a symptom-free interval. However, emerging evidence suggests that the \"migraine brain\" remains in a state of altered neuro-excitability and impaired habituation between attacks, manifesting as debilitating interictal symptoms. This narrative review aims to describe the spectrum of interictal symptoms, their underlying mechanisms, and their impact on the cumulative disease burden, at the same time as exploring the implications for clinical management.MethodsAn extensive literature search of the PubMed database was performed using terms related to the migraine cycle, interictal phase, and disease burden. Original articles published within the last 10 years were prioritized, focusing on clinical trials, real-world evidence, and neurophysiological studies.ResultsInterictal symptoms, including sensory hypersensitivity (photophobia, phonophobia, osmophobia, allodynia), cognitive dysfunction (\"brain fog\"), vestibular symptoms, and affective dysregulation, affect between 26% and 76% of patients. These symptoms significantly contribute to the socioeconomic burden of migraine, leading to substantial productivity losses (absenteeism and presenteeism) and reduced quality of life. While non-specific preventives often fail to alleviate interictal symptoms, calcitonin gene-related peptide-pathway targeted therapies and onabotulinumtoxinA have demonstrated promising results in reducing the interictal burden, as measured by standardized tools such as the Migraine Interictal Burden Scale (MIBS-4).ConclusionsMigraine management requires a paradigm shift from focusing solely on attack frequency to a more holistic approach that includes the interictal period. Standardizing interictal symptoms definitions and implementing specific outcome measures in clinical practice are essential to restore full functional capacity and provide comprehensive care for patients.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 11","pages":"3331024261502429"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2026-11-01Epub Date: 2026-11-03DOI: 10.1177/03331024261495542
Yooha Hong, Mi-Kyoung Kang, Soo-Jin Cho
{"title":"Atogepant for preventive treatment of episodic cluster headache: A single-center case series of 18 patients.","authors":"Yooha Hong, Mi-Kyoung Kang, Soo-Jin Cho","doi":"10.1177/03331024261495542","DOIUrl":"10.1177/03331024261495542","url":null,"abstract":"<p><p>BackgroundCluster headache (CH) is a highly disabling primary headache disorder characterized by severe unilateral attacks occurring in bouts. Calcitonin gene-related peptide plays a key role in CH pathophysiology, yet preventive treatment options remain limited. We aimed to evaluate the short-term clinical effects of atogepant in patients with episodic CH during an active cluster bout.MethodsWe conducted a single-center real-world observational study. The study protocol included both retrospective and prospective cohorts, but all patients in the present analysis were from the retrospective cohort. Adult patients with episodic CH treated with atogepant during an active bout were consecutively included. Weekly headache outcomes during baseline (the week prior to treatment) and week 1 after atogepant initiation were compared. The primary outcome was change in weekly headache days; secondary outcomes included attack frequency, pain intensity, attack duration, and acute medication use. Responder rates (≥ 50% reduction) and Patient Global Impression of Change (PGIC) were assessed.ResultsEighteen patients were included (mean age 39.9 ± 11.2 years; 72.2% male). Significant improvements were observed across all outcomes within one week after atogepant initiation. Weekly headache days decreased from 7.0 (5.0-7.0) to 3.0 (2.0-7.0) (<i>p</i> = 0.008), and attack frequency from 7.5 (5.5-14.0) to 3.0 (2.0-7.0) (<i>p</i> = 0.018). Pain intensity, attack duration, and acute medication use were also reduced. Large effect sizes were observed (r = 0.56-0.79). A ≥ 50% reduction in headache days occurred in 50.0% of patients and in attack frequency in 81.2%. PGIC ratings indicated that 66.7% of patients were rated as much or very much improved.DiscussionIn this open-label, uncontrolled study, atogepant initiation was associated with short-term improvements across multiple headache outcomes within one week in patients with episodic CH. Given the small sample size, retrospective data collection, short follow-up, and concurrent preventive therapies, these preliminary findings require confirmation in randomized, placebo-controlled trials.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 11","pages":"3331024261495542"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2026-11-01Epub Date: 2026-11-03DOI: 10.1177/03331024261495544
Miguel Saianda Duarte, Gonçalo Pinho, Raquel Gil-Gouveia
{"title":"Short-term gepant use during active cluster headache bouts: A consecutive case series.","authors":"Miguel Saianda Duarte, Gonçalo Pinho, Raquel Gil-Gouveia","doi":"10.1177/03331024261495544","DOIUrl":"10.1177/03331024261495544","url":null,"abstract":"<p><p>AimTo evaluate the short-term effectiveness and tolerability of gepants administered during active cluster headache (CH) bouts in routine clinical practice, focusing primarily on reduction in daily attack frequency and additionally on pain intensity, bout duration, and patient-reported outcomes.MethodsWe conducted an observational, uncontrolled, consecutive case series at a reference headache clinic. Patients fulfilling ICHD-3 criteria for episodic or chronic CH who initiated a standardized 28-day course of a gepant during an active bout between October 2024 and July 2025 were included. Baseline data were abstracted from clinical records and diaries. No systemic corticosteroids, greater occipital nerve blocks, preventive dose adjustments, or new preventives were introduced during the 28-day period. The primary endpoint was ≥50% reduction in mean daily attack frequency at the end of treatment compared with baseline. Secondary outcomes included change in pain intensity (Numerical Rating Scale, NRS), change in attack duration, impact on overall bout duration, Patient Global Impression of Change (PGIC), and adverse events. Analyses were descriptive.ResultsTen patients were included (seven episodic CH [ECH], three chronic CH [CCH]). Median baseline attack frequency was three attacks/day (range 1-6), and median baseline NRS was 8.5. The primary endpoint was achieved in 7/10 patients (70.0%): 5/7 with ECH (71.4%) and 2/3 with CCH (66.7%). Two ECH patients with a low baseline frequency (two attacks/day) did not meet the ≥50% criterion but demonstrated marked reductions in pain intensity and shortened bout duration. Overall, pain intensity improved in 9/10 patients (90.0%), with a median NRS reduction of 7 points (range 0-10). Median intensity reduction was greater in ECH (7 points; range 2-10) than in CCH (2.5 points; range 0-5). Shortening of individual attacks was reported in 4/10 (40.0%), and reduction in overall bout duration in 7/10 (70.0%), predominantly among ECH. Median time to perceived benefit was 96 h. Adverse events were mild (nausea or constipation in 2/10).ConclusionIn this small real-world case series, short-term gepant use during active cluster bouts was associated with multidimensional clinical improvement, particularly in episodic CH. Benefits extended beyond attack frequency to include substantial reductions in pain intensity and apparent modulation of bout duration. Given the uncontrolled design and limited sample size, findings should be interpreted cautiously but support further prospective, phenotype-stratified investigation.</p>","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 11","pages":"3331024261495544"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2026-11-01Epub Date: 2026-11-03DOI: 10.1177/03331024261501136
Timothy J Steiner, Andreas Kattem Husøy
{"title":"Uludüz D et al. Migraine and headache in children and adolescents: A 2026 evidence-based factsheet.","authors":"Timothy J Steiner, Andreas Kattem Husøy","doi":"10.1177/03331024261501136","DOIUrl":"https://doi.org/10.1177/03331024261501136","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 11","pages":"3331024261501136"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2026-11-01Epub Date: 2026-11-11DOI: 10.1177/03331024261507500
Faraidoon Haghdoost, Carl Cincinnato
{"title":"Migraine is chronic - its frequency varies: Time to reconsider 'episodic' and 'chronic' migraine terminology.","authors":"Faraidoon Haghdoost, Carl Cincinnato","doi":"10.1177/03331024261507500","DOIUrl":"https://doi.org/10.1177/03331024261507500","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 11","pages":"3331024261507500"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2026-11-01Epub Date: 2026-11-10DOI: 10.1177/03331024261506164
Paulien J van Tilborg, Rolf Fronczek
{"title":"Beyond pacing: What does restlessness really mean in cluster headache?","authors":"Paulien J van Tilborg, Rolf Fronczek","doi":"10.1177/03331024261506164","DOIUrl":"https://doi.org/10.1177/03331024261506164","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 11","pages":"3331024261506164"},"PeriodicalIF":5.8,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149377662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
CephalalgiaPub Date : 2026-10-01DOI: 10.1177/03331024261493112
Bradley Ong, Sedat Gül
{"title":"Reply to: interpreting discordant negative-control outcomes in the cerebrovascular safety assessment of CGRP monoclonal antibodies.","authors":"Bradley Ong, Sedat Gül","doi":"10.1177/03331024261493112","DOIUrl":"https://doi.org/10.1177/03331024261493112","url":null,"abstract":"","PeriodicalId":10075,"journal":{"name":"Cephalalgia","volume":"46 10","pages":"3331024261493112"},"PeriodicalIF":5.8,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}